Pfizer projects 2026 revenue between $60.5 billion and $62.5 billion while aiming for $9.7 billion in net cost reductions by 2029.
Pfizer announced a 2026 revenue guidance range of $60.5 billion to $62.5 billion during its Q2 2026 earnings call, citing strong execution and strategic progress. The company also outlined plans to achieve $9.7 billion in net cost savings through 2029.
The guidance follows a period of operational focus, with management highlighting continued momentum in its core businesses. Comparable revenue figures for prior periods were not disclosed, but the savings target reflects ongoing efforts to streamline operations.
CEO Albert Bourla emphasized the company’s commitment to delivering long-term value, though no immediate market reaction was detailed in the call.